This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEI1D01M_L.jpg
The company will deliver 800,000 courses of the antiviral molnupiravir to Japan by March, up from an earlier scheduled 600,000, it said in a statement.
Japan agreed last year to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of molnupiravir. The drug was approved by regulators in late December.
